Male subjects agree to remain abstinent or use a condom plus an additional contraceptive method that result in a failure rate of < % per year during sexual contact with a female of childbearing potential while participating in the study, during dose interruptions, and for  weeks following the last dose of the study treatment, even if he has undergone a successful vasectomy; abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the patient; periodic abstinence and withdrawal are not acceptable
Practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of child bearing potential while participating in the study, during dose interruptions and for at least  days following pomalidomide discontinuation, even if he has undergone a successful vasectomy or practices complete abstinence.
For this trial, male subjects must practice abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for  months following protocol discontinuation, even if he has undergone a successful vasectomy
Male subjects must practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for  days following treatment discontinuation, even if he has undergone a successful vasectomy
Male subjects with a female partner of childbearing potential must commit to true abstinence from heterosexual contact or commit to the use of male condom plus spermicide throughout the course of the study, and avoid fathering a child during the course of the study (including dose interruptions) and for  months following the last dose of azacitidine
Male subjects must practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for  months following IP discontinuation, even if he has undergone a successful vasectomy
Male subjects must practice true abstinence or agree to use a condom during sexual contact with a pregnant female or female of childbearing potential starting with the first dose of study therapy, during dose interruptions, and for up to  months following last dose of study therapy, even if he has undergone a successful vasectomy
Male subjects must practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for  months following IP discontinuation, even if he has undergone a successful vasectomy
Male subjects must practice true abstinence or agree to use a condom during sexual contact with a female of childbearing potential or a pregnant female while on treatment (including during dose interruptions) with gemcitabine/cisplatin/nab-paclitaxel and for  months following gemcitabine/cisplatin/nab- paclitaxel discontinuation, even if he has undergone a successful vasectomy.
Must practice true abstinence* or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least  days following lenalidomide discontinuation, even if he has undergone a successful vasectomy or practices complete abstinence.
Male subjects agree in writing to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for  months following IP discontinuation, even if he has undergone a successful vasectomy.
Practice true abstinence (which must be reviewed on a monthly basis) or agree to use a condom during sexual contact with a pregnant female or a FCBP while participating in the study, during dose interruptions and for at least  days following study treatment discontinuation, even if he has undergone a successful vasectomy.
Either practice true abstinence from heterosexual contact (which must be reviewed on a monthly basis) or agree to avoid fathering a child, to use highly effective methods of contraception, male condom plus spermicide during sexual contact with a pregnant female or a female of childbearing potential (even if he has undergone a successful vasectomy) from starting dose of IP (Cycle  Day ), including dose interruptions through  days after receipt of the last dose of durvalumab or azacitidine.
Male participants who disagree to practice true abstinence or disagree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and at least  months following study treatment discontinuation, even if he has undergone a successful vasectomy.
All males, regardless of whether they have undergone a successful vasectomy, must agree to use a latex condom during sexual contact with a female of childbearing potential, or to practice complete abstinence from heterosexual intercourse with any female of childbearing potential during all cycles of study treatment and for at least  days following discontinuation of protocol treatment
Male subjects must practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for  months following treatment discontinuation, even if he has undergone a successful vasectomy
practice true abstinence* or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least  months following study drug discontinuation, even if he has undergone a successful vasectomy.
Must practice complete abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least  days following study drug discontinuation, even if he has undergone a successful vasectomy.
Male subjects must practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during those interruptions and for  months following IP discontinuation, even if he has undergone a successful vasectomy
Either practice true abstinence from heterosexual contact (which must be reviewed on a monthly basis) or agree to avoid fathering a child, to use highly effective methods of contraception, male condom plus spermicide during sexual contact with a pregnant female or a female of child bearing potential (even if he has undergone a successful vasectomy) from starting dose of IP (Cycle  Day ), including dose interruptions through  days after receipt of the last dose of azacitidine.
